Page 25:Candidate product discovery and translational Biology...

Page 25:

Candidate product discovery and translational Biology Programs

Alterity’s intellectual property is considered “platform technology” based on our approach that a broad spectrum of neurodegenerative and agerelated diseases can be addressed by targeting the interrelationship of metals and proteins. Historically, the majority of our research efforts have been
directed at research into potential therapeutics for the treatment of Alzheimer’s disease, Huntington disease and Parkinsonian disorders. Published data together with our initial findings have provided strong indications that the pathology for other certain age-related and degenerative disorders may also be based on the interaction between certain metals and proteins, and we believe that the platform technology may also be applicable for certain cancers, age-related macular degeneration, diabetes mellitus, cardiovascular disease, and other neurodegenerative diseases.
To date, we have performed in vivo evaluations of our product candidates in a range of animal models of disease including parkinsonian
disorders, Alzheimer’s disease, Huntington disease, and brain cancer.